[18F]AlF-PSMA-11 PET/CT在放射性碘难治性甲状腺癌中的潜在应用
这项II期研究纳入8例放射性碘难治性甲状腺癌患者,比较[18F]AlF-PSMA-11 PET与[18F]FDG PET/CT的病灶检出,39个病灶中两者分别检出30个和33个(检出率76.9%和84.6%),6个病灶仅被PSMA PET显示。作者认为PSMA靶向显像在此类患者中具有潜在额外诊断价值。
要点
- 39个病灶中[18F]AlF-PSMA-11 PET检出30个(76.9%),[18F]FDG PET检出33个(84.6%)。
- 9个病灶仅[18F]FDG显示,6个病灶仅[18F]AlF-PSMA-11 PET显示。
- 8例中5例原发肿瘤组织免疫组化显示PSMA表达。
核心结论
- 尽管并非所有病灶均可显示,[18F]PSMA-11 PET检出了多个[18F]FDG PET未能察觉的病灶,显示PSMA靶向显像在放射性碘难治性甲状腺癌患者中具有潜在的额外诊断作用。
研究设计与样本
- II期研究,纳入8例放射性碘难治性甲状腺癌患者,将[18F]AlF-PSMA-11 PET检出的病灶与[18F]FDG PET/CT结果比较。
- 采用ELISA测定血清可溶性PSMA(sPSMA),并对可获得的切除标本用免疫染色仪分析肿瘤组织PSMA表达。
主要发现
- 基于PET显像共识别39个病灶,[18F]AlF-PSMA-11 PET检出30个(检出率76.9%),[18F]FDG PET检出33个(84.6%)。
- 9个病灶仅[18F]FDG显示,6个病灶仅[18F]AlF-PSMA-11 PET显示。
- 所有女性患者sPSMA均不可测;男性患者sPSMA与疾病相关因素之间未发现相关性。
- 8例中5例免疫组化显示原发肿瘤PSMA表达。
关键数值与推荐
- [18F]AlF-PSMA-11 PET检出39个病灶中的30个,检出率76.9%。
- [18F]FDG PET检出39个病灶中的33个,检出率84.6%。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients diagnosed with radioiodine refractory (RAI-R) thyroid carcinoma (TC) have a significantly worse prognosis than patients with radiosensitive TC. These refractory malignancies are often dedifferentiated, hindering the effectiveness of iodine-based imaging. Additionally, the role of metabolic imaging using [18F]FDG PET/CT is also limited in these cases, making adequate staging of RAI-R TC challenging. Recent case series have shown promising results regarding the role of the prostate-specific membrane antigen (PSMA) in TC. In this study we explored the value of [18F]AlF-PSMA-11 PET/CT in RAI-R TC. METHODS: In this phase II study, lesions detected on [18F]AlF-PSMA-11 PET were compared to findings from [18F]FDG PET/CT. Additionally, the serologic soluble prostate-specific membrane antigen (sPSMA) was measured using ELISA. PSMA-expression on tumor tissue in any available resection specimens was analysed with an immunostainer. RESULTS: Eight patients were included, with a total of 39 identified lesions based on PET imaging. [18F]AlF-PSMA-11 PET identified 30 of 39 lesions, and [18F]FDG PET identified 33 lesions, leading to a detection rate of 76.9% and 84.6%, respectively. Interestingly, while nine lesions were solely visualized on [18F]FDG, six were uniquely seen on [18F]AlF-PSMA-11 PET. While sPSMA was immeasurable in all female patients, no correlation was found between sPSMA in male patients and disease-related factors. In five out of eight patients immunohistology showed PSMA expression on the primary tumor. CONCLUSIONS: Although not all lesions could be visualized, [18F]PSMA-11 PET identified multiple lesions imperceptible on [18F]FDG PET. These results display the potential additional diagnostic role of PSMA-targeted imaging in patients with RAI-R TC. Trial registration number No. EudraCT 2021-000456-19.
引用
- Van den Broeck B, Debacker JM, Bauters W, et al. Potential application of [18F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma. EJNMMI Res. 2024. PMID: 39264376. doi:10.1186/s13550-024-01148-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。